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Monoclonal antibody (mAb) technology is an excellent tool for the discovery of overexpressed cell 
surface tumour antigens and the development of targeting agents. Here, we report the development 
of two novel mAbs against CFPAC-1 human pancreatic cancer cells. Using ELISA, flow cytometry, 
immunoprecipitation, mass spectrometry, Western blot and immunohistochemistry, we found that 
the target antigens recognised by the two novel mAbs KU44.22B and KU44.13A, are integrin α3 and 
CD26 respectively, with high levels of expression in human pancreatic and other cancer cell lines and 
human pancreatic cancer tissue microarrays. Treatment with naked anti-CD26 mAb KU44.13A did not 
have any effect on the growth and migration of cancer cells nor did it induce receptor downregulation. 
In contrast, treatment with anti-integrin α3 mAb KU44.22B inhibited growth in vitro of Capan-2 cells, 
increased migration of BxPC-3 and CFPAC-1 cells and induced antibody internalisation. Both novel 
mAbs are capable of detecting their target antigens by immunohistochemistry but not by Western 
blot. These antibodies are excellent tools for studying the role of integrin α3 and CD26 in the complex 
biology of pancreatic cancer, their prognostic and predictive values and the therapeutic potential of 
their humanised and/or conjugated versions in patients whose tumours overexpress integrin α3 or 
CD26.
Pancreatic cancer remains one of the deadliest cancer types. In 2018, there were an estimated 458,918 new cases 
of pancreatic cancer, and 432,242 deaths as a result of pancreatic cancer in 185 countries worldwide1,2. Pancreatic 
cancer is predicted to become the second leading cause of cancer death after lung cancer, within the next decade 
in Western countries3.
At present, the only curative treatment for patients with pancreatic cancer is surgery. However, only a minority 
of patients are eligible for resection and disease recurrence is a frequent event in many such patients. Historically, 
gemcitabine-based therapy has been the mainstay for treatment of pancreatic cancer4. More recently the com-
bination of gemcitabine plus capecitabine has been regarded as the new standard of care in the adjuvant set-
ting5. Patients with metastatic disease are treated with either FOLFIRINOX or gemcitabine plus nab-paclitaxel as 
first-line in patients with good performance status6,7.
In order to reduce the dismal pancreatic cancer mortality rates, it is essential to discover novel biomarkers for 
use in the early detection of pancreatic cancer, to discover novel therapeutic targets and to develop novel and more 
effective therapeutic agents8,9. Monoclonal antibodies (mAbs) are excellent tools for the discovery of novel over-
expressed cell surface antigens and their specific targeting for diagnostic and therapeutic purposes10,11. To date, 
36 mAbs have been approved for cancer treatment in the U.S. and/or European Union, although none for pan-
creatic cancer yet12,13. As tumour heterogeneity has been reported both between (i.e. inter-tumour heterogeneity) 
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and within tumours (i.e. intra-tumour heterogeneity) in patients with pancreatic cancer, and between primary 
tumours and their metastatic counterparts, it has not been possible to find a magic and universal drug for the 
treatment of such patients14,15. As a result, over the past few years, our work has been focused on the discovery 
of overexpressed cell surface antigens in human pancreatic cancer using a panel of pancreatic cancer cell lines 
derived from patients at different stages of their disease as the source of tumour immunogen and in the antibody 
screening and the study of such mAbs for use in cancer diagnosis and therapy. We reported recently the develop-
ment of two novel antibodies against an antigen with high level of expression in pancreatic cancer (i.e. CD109) 
using the human pancreatic cancer cell line BxPC-3 (derived from a primary tumour) as the source of tumour 
immunogen9,16. BxPC-3 is a moderate to poorly differentiated cell line derived from a 61-year-old Caucasian 
female with a primary body of pancreas adenocarcinoma in whom no metastatic disease was found and who 
died 6 months later despite chemotherapy and radiation16. Here, we report the development of two novel mouse 
mAbs using CFPAC-1, a cancer cell line established from liver metastasis of a patient with pancreatic cancer, as 
the source of tumour immunogen17. As there is no complete concordance between the expression level of some 
genes and their protein products in the primary pancreatic cancer and the corresponding metastatic lesions, 
our strategy was to develop other antibodies against antigens with high levels of expression in the primary and/
or metastatic pancreatic cancer using both the primary and metastatic pancreatic cancer cell lines as immuno-
gen18–21. Indeed, some of the immunogenic antigens may only be overexpressed in the primary tumour cells (i.e. 
BxPC-3) and not the metastatic pancreatic tumour cells and vice versa. Using a panel of human pancreatic cancer 
cell lines established from patients at different stages of their diseases and tumour tissue arrays from patients with 
pancreatic cancer, we found that the overexpressed target antigens recognised by these two novel antibodies are 
integrin α3 and CD26. Thus, in addition to their diagnostic and therapeutic potential, these antibodies will be 
valuable tools for unravelling the role of integrin α3 and CD26 in the progression and complex biology of pan-
creatic cancer
Results
Development of two novel mouse mAbs KU44.22B and KU44.13A. A panel of hybridomas was 
generated by fusing lymphocytes from mice immunised with CFPAC-1 human pancreatic cancer cells and SP2 
myeloma cells. Flow cytometry and ELISA revealed that the antigen recognised by mAb KU44.22B was widely 
expressed across pancreatic and other cancer cell lines, particularly in the human pancreatic cancer cells BxPC-3 
(MFI = 357), CFPAC-1 (MFI = 283), AsPC-1 (MFI = 265) and Capan-2 (MFI = 107), as well as the ovarian can-
cer cell lines SKOV-3 (MFI = 687) and CaOV-3 (MFI = 836), the glioblastoma cell line A172 (MFI = 466) and the 
head and neck cancer cell line HN-5 (MFI = 118; Fig. 1 and Supplementary Figs. 1 and 2). On the other hand, 
mAb KU44.13A recognised an antigen with overexpression limited to AsPC-1 human pancreatic cancer cells 
(MFI = 437) and to a lower extent HPAF-II (MFI = 48) and the ovarian cell line SKOV-3 (MFI = 38; Fig. 1 and 
Supplementary Figs. 1 and 2). While in the ELISA, cancer cell monolayers were treated with the primary anti-
bodies, for flow cytometry tumour cells were treated with trypsin prior to incubation with the primary antibody. 
As the results of ELISA show, the highest levels of target antigen recognised by mAb KU44.13A were found in 
human pancreatic cancer cell lines derived from ascites (i.e. AsPC-1 and HPAF-II) and lymph node metastasis 
(Supplementary Fig. 1). Using the mouse isotyping kits, novel mAbs KU44.22B and KU44.13A were found to be 
of IgG1κ and IgG2a isotypes respectively (data not shown).
The two novel mAbs KU44.22B and KU44.13A are directed against integrin α3 and CD26 
respectively. The results of SDS-PAGE stained gels showed that mAb KU44.22B immunoprecipitated a 140 
KDa protein identified as integrin α3 by mass spectrometry whereas mAb KU44.13A immunoprecipitated a 
Figure 1. Expression level of the antigens recognised by novel mAbs KU44.22B and KU44.13A on human 
pancreatic and other cancer cell lines determined by flow cytometry.
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protein of approximately 110 kDa corresponding to CD26 from the lysates of CaOV3 and ASPC-1 cells respec-
tively (Fig. 2A,B left panel, and Table 1, full-length gels are presented in Supplementary Fig. 3). In addition, using 
the lysis buffer described in methods, mAb KU44.22B precipitated a protein of approximately 260 kDa that could 
not be identified by mass spectrometry (Fig. 2A, left panel). However, using RIPA lysis buffer, this additional pro-
tein was not immunoprecipitated by mAb KU44.22B (Supplementary Fig. 3C). The faint protein band of ~65 KDa 
in the antibody samples and controls yielded a single peptide which matched to serum albumin. Neither of the 
two novel mAbs were able to detect the target antigens by Western blot (Fig. 2A,B, middle panel). To confirm the 
identity of the target antigens, immunoprecipitation with the novel mAbs and the anti-integrin α3 and anti-CD26 
commercial antibodies, followed by immunodetection by Western blot with the same commercial antibodies was 
performed. As shown in Fig. 2A,B, right panel, both antigens were immunodetected with the commercial mAbs.
MAb KU44.22B inhibits the growth in vitro of Capan-2 cancer cells, increases migration of 
BxPC-3 and CFPAC-1 cancer cell lines and induces receptor downregulation and internalisa-
tion. We investigated the effect of treatment with these two novel antibodies on the growth and migration in 
vitro of a panel of human pancreatic and other cancer cell lines. At 300 nM, mAb KU44.22B inhibited the growth 
of Capan-2 human pancreatic cancer cells by 94% with an IC50 value of 4.5 nM (Fig. 3) whereas it inhibited the 
growth of CFPAC-1 cells by 20% (data not shown). Interestingly, treatment with this mAb did not have any effect 
on the growth of the other cell lines tested including the ovarian cancer cell lines SKOV-3 and CaOV-3, and the 
glioblastoma cell line A172, despite having higher levels of integrin α3 cell surface expression than Capan-2 cells 
(data not shown). On the other hand, treatment with mAb KU44.22B increased migration of BxPC-3 and to a 
lesser extent CFPAC-1 cancer cells (Fig. 4) and induced-receptor downregulation and internalisation (Fig. 5). In 
contrast, treatment with mAb KU44.13A did not have any effect on the growth or migration of any of the cell lines 
tested and did not induce receptor downregulation (data not shown, and Fig. 5).
Immunohistochemical detection of the antigen recognised by novel mAbs KU44.22B and 
KU44.13A. To explore the diagnostic potential of the novel mAbs, immunohistochemical staining was per-
formed in Capan-2 (mAb KU44.22B) and AsPC-1 (mAb KU44.13A) tumour cell pellets. The results showed that 
both mAbs were able to immunodetect the target antigens in formalin-fixed paraffin-embedded tumour sections 
(Figs. 6 and 7).
Then, we examined the relative expression of integrin α3 and CD26 (immunodetected by mAbs KU44.22B 
and KU44.13A respectively) in tissue arrays containing 48 specimens from patients with pancreatic cancer. Of 
these, three samples contained no tumour in the integrin α3 slide and 14 in the CD26 slide and therefore were 
excluded from the study. Of 45 cases, 64% of tissue samples were integrin α3 positive, with intensity ranging 
from 1 + weak (n = 17, 37.8%) to 2+ moderate (n = 12, 26.6%). Staining predominated in the membrane and/
or the cytoplasm of cancer cells and did not correlate with the disease grade (Fig. 6C–E; Supplementary Table 1). 
In contrast, normal pancreatic tissue was negative or showed only weak cytoplasmic diffuse staining (Fig. 6F).
On the other hand, of 34 cases, CD26 was overexpressed in 64% of samples, with intensity 1 + weak (n = 16, 
47.6%) to 2 + moderate (n = 6, 17.7%; Fig. 7C–E; Supplementary Table 2). Similarly, there was no correlation with 
tumour grading and weak cytoplasmic staining was seen in normal pancreatic tissue (Fig. 7F).
Discussion
Pancreatic cancer is a highly aggressive and devastating cancer type, responsible for an increasing number of 
cancer related incidence and deaths1,2,22. The complex biology of pancreatic cancer and its microenvironment, the 
unavailability of reliable biomarkers for its early detection, the non-specific clinical presentation and the primary 
and secondary resistance to current therapeutic interventions are some of the attributing factors. Therefore, to 
improve the poor outcomes for patients diagnosed with pancreatic cancer, it is imperative to develop a screening 
technique for its early diagnosis, to discover novel therapeutic targets and to develop more effective and less toxic 
therapeutic agents. Monoclonal antibodies are excellent agents for use in both diagnosis and therapy of human 
cancer. The exquisite specificity of the antibodies for the target antigen also makes them ideal tools for investi-
gating the biological, diagnostic, prognostic and predictive value of their target antigens and for use in targeted 
therapy of human cancers10,11,23,24. We have previously reported the generation of two novel anti-CD109 mAbs by 
means of hybridoma technology using BxPC-3 human pancreatic cancer cells, a cell line derived from a primary 
tumour, as the source of immunogen9. However, human cancers are heterogeneous in nature, a characteristic 
feature which contributes to the response of short duration or development of resistance to current therapies21. 
Both inter-tumour heterogeneity (i.e. heterogeneity between individuals), and intra-tumour heterogeneity (i.e. 
heterogeneity within the same tumour) as well as heterogeneity between the primary tumour and its metastatic 
counterparts have been reported in pancreatic cancer14,15,19. Here, using the human pancreatic cancer cell line 
CFPAC-1, which was isolated from a patient with liver metastasis, we describe the production and characterisa-
tion of two other novel mAbs. We have shown that these two novel antibodies are directed against integrin α3 
(KU44.22B) and CD26 (KU44.13A).
We found overexpression of the target antigen integrin α3 recognised by the novel mAb KU44.22B in several 
human pancreatic cancer cell lines as well as human glioblastoma, ovarian and head and neck cancer cell lines 
as determined by ELISA and flow cytometry (Fig. 1 and Supplementary Figs. 1 and 2). This mAb inhibited the 
growth in vitro of Capan-2 cells (Fig. 3), increased migration of BxPC-3 and CFPAC-1 cells (Fig. 4) and induced 
receptor downregulation and internalisation (Fig. 5). While mAb KU44.22B was not able to recognise integrin α3 
by Western blot, it proved useful for the immunohistochemical detection of the target antigen in formalin-fixed 
paraffin-embedded tissue sections from cancer cell pellets and tissue microarrays (Figs. 2 and 6).
Integrins are a family of heterodimeric (αβ) cell surface receptors that participate in cell-cell and cell-matrix 
interactions25. Their 18 α and 8 β subunits associate in different combinations and form at least 24 heterodimers 
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Figure 2. Immunoprecipitation and immunodetection by Western blot of (A) integrin α3 and (B) CD26 
antigen with novel mAbs KU44.22B and KU44.13A using lysates from CaOV-3 ovarian cancer cells and AsPC-1 
pancreatic cancer cells respectively. Left panel: Immunoprecipitation was performed with novel mAbs (A) 
KU44.22B and (B) KU44.13A (5 µg) using sheep anti-mouse dynabeads. Protein bands around ~140 KDa and 
~ 260KDa were immunoprecipitated with mAb KU44.22B (A; left panel) and ~110 KDa by mAb KU44.13A (B; 
left panel) respectively and stained with SimplyBlue™ SafeStain. The ~50/25 KDa bands represent heavy and 
light chains of the anti-mouse antibody. *(B) left panel corresponds to a cropped gel; vertically sliced images 
of juxtaposed lanes that were non-adjacent in the gel have a clear separation delineating the boundary between 
the gels. Middle panel: Integrin α3 and CD26 antigen were immunoprecipitated with mAbs (A) KU44.22B and 
(B) KU44.13A (5 µg) respectively, and probed with the same antibody (30 µg/ml). Target antigens were not 
immunodetected with either of the mAbs. Right panel: Integrin α3 and CD26 antigen were immunoprecipitated 
with mAbs (A) KU44.22B and (B) KU44.13A respectively (5 µg) or commercial anti-integrin α3 and 
anti-CD26 antibodies (2 µg) and immunodetected with commercial mAbs sc-374242 and ab89398 as described 
in Methods. Immunodetection of target antigens immunoprecipitated by novel mAbs and probed with 
commercial mAbs confirmed the target identity. MW: molecular weight marker.
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with functional and tissue specificity26. Of these, integrin α3 (also known as ITGA3, CD49c, and VLA-3 subunit 
alpha) is a 140 KDa protein thought to be involved in the hepatocyte growth factor (HGF)/c-Met signal pathway 
contributing to tumour progression27. The integrin α3 subunit is believed to join a β1 subunit to form a complex 
that interacts with extracellular matrix proteins including members of the laminin family28. To our knowledge, 
Band No. mAb
Protein Hits
Matches/Sequences
1 KU44.13A
P27487 Dipeptidyl peptidase 4/CD26 OS = Homo sapiens GN = DPP4 
PE = 1 SV = 2
Mass: 88907 Score: 198 Matches: 5(5) Sequences: 3(3)
Start-End Score Peptide
176–184 35 K.IEPNLPSYR.I
598–611 89 R.LGTFEVEDQIEAAR.Q
659–669 73 R.WEYYDSVYTER.Y
2 KU44.22B P26006 Integrin alpha-3 OS = Homo sapiens GN = ITGA3 PE = 1 SV = 5Mass: 117735 Score: 245 Matches: 4(4) Sequences: 4(4)
Start-End Score Peptide
44–60 107 K.EAGNPGSLFGYSVALHR.Q
68–76 46 R.YLLLAGAPR.E
144–156 67 R.YTQVLWSGSEDQR.R
462–471 27 R.ARPVINIVHK.T
Table 1. Identification of proteins recognised by novel mAbs KU44.13A and KU44.22B by mass spectrometry.
Figure 3. Effect of novel mAb KU44.22B on the growth of Capan-2 human pancreatic cancer cells determined 
by SRB assay as described in Methods. Novel mAb KU44.22B inhibits the growth of Capan-2 human pancreatic 
cancer cells with IC50 = 4.5 nM.
Figure 4. Effect of novel mAbs KU44.22B and KU44.13A on the migration of BxPC-3 and CFPAC-1 human 
pancreatic cancer cells using the IncuCyte ZOOM® Live-Cell Imaging instrument (Essen Bioscience, UK) 
as described in Methods. Treatment with mAb KU44.22B (300 nM) significatively increases the migration of 
BxPC-3 and CFPAC-1 cells.
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this is the first report of anti-tumour activity in vitro of an anti-integrin α3 antibody in pancreatic cancer. At 
300 nM, mAb KU44.22B inhibited the growth of Capan-2 cells by 94% and with an IC50 value of 4.5 nM (Fig. 3). 
However, as our hybridomas were grown in medium containing 3% FBS. it may be possible that the mouse anti-
bodies purified on Protein G affinity column contain low level of calf antibodies. If this is the case, the actual IC50 
value of mAb KU44.22B in Capan-2 cells could be even lower than 4.5 nM. The adaptation of the mouse hybri-
doma grown in serum-free medium or the purification of the mouse hybridoma supernatants using anti-mouse 
IgG affinity column could help increase the purity of the antibodies by eliminating potential contaminant calf 
antibodies. In another study, a mouse mAb (BCMab1), which was raised against aberrantly glycosylated integrin 
α3β1 on the human bladder cancer cell line T24, was accompanied by potent antitumor activity in subcutaneous 
and orthotopic bladder cancer mouse models29. Interestingly, we found that the anti-tumour activity of mAb 
KU44.22B was limited only to Capan-2 cells despite the high level of expression of its target antigen in other can-
cer cell lines (Fig. 1), which suggests that Capan-2 cell line is more dependent on integrin α3 for survival than any 
of the other cell lines examined. Further studies should be conducted to unravel the biological mechanisms that 
determine response to treatment with anti-integrin α3 mAb KU44.22B and to develop and investigate the thera-
peutic potential of the humanised version of this antibody in tumours with high levels of anti-integrin α3 in vivo.
Since Capan-2 is a non-migratory pancreatic cell line, the effect mAb KU44.22B on its migration could 
not be explored. However, treatment of BxPC-3 and CFPAC-1 cells with KU44.22B was accompanied by an 
increase in the migration of these tumour cells in vitro (Fig. 4). Indeed, integrin α3 has been reported to have 
both pro-migratory and anti-migratory effects in different tumour types. For example, depletion of integrin α3 
was reported to increase the migration of prostate cancer cell lines and has been correlated with the disease grade 
and stage in prostate cancer30. Similarly, low integrin α3 expression was found to be associated with increased 
metastasis of certain colon cancers31. In contrast, in other studies integrin α3 was reported to have opposite effect 
by being overexpressed in glioma stem-like cells and contributing to the invasive nature of such cells32,33. ITGA3 
(the protein coding gene for integrin α3) was found to be significantly associated with higher risk of recurrence 
Figure 5. Internalisation studies of novel mAbs KU44.22B and KU44.13A in BxPC-3 and AsPC-1 human 
pancreatic cancer cells determined by (A,B) Immunofluorescence, BxPC-3 and AsPC-1 cancer cells were grown 
to near confluency and incubated with purified mAbs KU44.22B and KU44.13A respectively (50 μg/ml) or 
control (PBS/1% BSA) at 4 °C for 1 h and subsequently at 37 °C for extra 30 min to allow internalisation. Cells 
were then fixed, permeabilised and incubated with anti-mouse secondary antibody (Alexa Fluor 488; 1:200) at 
4 °C for 1 h for detection using Nikon eclipse i80 microscope; and (C,D) ELISA, BxPC-3 and AsPC-1 cancer 
cells were grown to near confluency 96-well plates and incubated with purified mAbs KU44.22B and KU44.13A 
respectively (50 μg/ml) or control (PBS/1% BSA) at 4 °C for 1 h and subsequently at 37 °C for extra 30 min to 
allow internalisation. Cells were then fixed, permeabilised and incubated with HRP-conjugated rabbit anti-
mouse (1:1000, STAR13B, AbD Serotec) and the absorbance of each sample measured at 450 nm.
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and lower DFS in patients with colorectal tumours34 and shorter survival in pancreatic cancer35. High levels of 
ITGA3 correlate with more aggressive phenotypes and poor prognosis in patients with colorectal cancer and pan-
creatic ductal adenocarcinoma36,27. More recently, in another study overexpression of ITGA3 has been associated 
with a poor prognosis in patients with pancreatic cancer and ablation of ITGA3 was reported to be accompanied 
by a significant decrease in the EGFR expression and tumour growth37. ITGA3 expression may therefore be a 
biomarker of diagnostic and prognostic values in pancreatic cancer38. Our study here demonstrated integrin α3 
overexpression in a wide TMA from pancreatic cancer patients by IHC with weak staining of normal pancreatic 
tissue (Fig. 6). Further studies with mAb KU44.22B are warranted and should help to determine the expression 
pattern, prognostic significance and predictive value of integrin α3 in patients with pancreatic cancer and other 
forms of cancer. This antibody is also an excellent tool in helping us understand the complex role of integrin α3 
in tumour biology and its potential as target for therapy with monoclonal antibody-based drugs and other forms 
of therapeutics26.
Using immunoprecipitation followed by mass spectrometry, we found that the antigen recognised by the 
second mAb KU44.13A is CD26. Of the cell lines examined, CD26 overexpression was found to be limited to 
those derived from ascites specifically AsPC-1 pancreatic cells and to a lower extent HPAF-II pancreatic cancer 
cells and SKOV-3 ovarian cancer cells (Fig. 1 and Supplementary Figs. 1 and 2). Treatment with anti-CD26 mAb 
Figure 6. Examples of immunohistochemical staining of formalin-fixed, paraffin-embedded Capan-2 cancer 
cell pellets (A-B) and human pancreatic tissue microarrays (C–F) using novel mAb KU44.22B (15 μg/ml). 
Staining was performed as described in Methods section. (A) Negative control; (B) Staining of Capan-2 cells 
with mAb KU44.22B; (C) 2/3 + membrane, 2 + cytoplasm (C7); (D) 2 + membrane (B5); (E) 2 + membrane, 
1 + cytoplasm (C3); (F) Normal pancreas tissue (F3); magnification 200×.
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KU44.13A did not have any effect on cell proliferation, migration or receptor downregulation on the cell lines 
tested (data not shown and Fig. 5). While this mAb was not able to detect CD26 by Western blot, it was capable of 
detecting CD26 by immunohistochemistry in formalin-fixed paraffin-embedded tissue sections (Figs. 2 and 7).
CD26 (also known as Dipeptidyl peptidase-4 [DPP4/DPPIV] or ADCP2) is a 110 KDa membrane-associated 
peptidase. It is expressed in endothelial cells, fibroblasts and lymphocytes, on the apical surfaces of epithelial and 
acinar cells, and in a soluble form in plasma39. It is believed to play a role in tumour development through its 
association with intracellular proteins and its effect seems to be dependent on the tumour type and its microen-
vironment40. While CD26 has been shown to have a tumour suppressor effect in melanoma, ovarian cancer, 
non-small cell lung cancer, prostate cancer, endometrial cancer, neuroblastoma and glioma cell lines, it has been 
reported to be a marker of tumour aggressiveness in T-anaplastic large cell lymphoma, T-leukaemia, malignant 
mesothelioma, colorectal cancer and Ewing sarcoma cell lines40,41. Furthermore, CD26 has been reported to have 
higher levels of expression in pancreatic cancer tissue than in normal tissue and knockdown of CD26 expression 
inhibited cell growth, migration, invasion and colony formation, increases cell apoptosis of pancreatic cancer cells 
in vitro and decreased tumour growth and liver metastasis in vivo42. CD26 has been reported to be secreted in the 
serum of patients with different cancer types and therefore it has been proposed as a potential tumour biomarker 
Figure 7. Examples of immunohistochemical staining of formalin-fixed, paraffin-embedded AsPC-1 cancer 
cell pellets (A-B) and human pancreatic tissue microarrays (C–F) using novel mAb KU44.13A (10 μg/ml). 
Staining was performed as described in Methods section. (A) Negative control; (B) Staining of AsPC-1 
cells with mAb KU44.13A; (C) 2 + membrane, 1 + cytoplasm (C3); (D) 1 + membrane/cytoplasm (B3); (E) 
2 + cytoplasm/membrane (D4); (F) Normal pancreas tissue (F8); magnification 200×.
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of diagnostic and prognostic value in a wide range of cancers including pancreatic cancer40–42. CD26 has also been 
suggested as a cancer stem cell marker in different types of cancer and a potential therapeutic target43–45.
Although our anti-CD26 novel mAb KU44.13A did not show any effect on cell proliferation or migration 
on the panel of cell lines evaluated in this study, treatment with other anti-CD26 monoclonal antibodies have 
shown to reduce tumour growth in vitro and in vivo and improve survival in malignant mesothelioma, renal cell 
carcinoma and anaplastic large cell T-cell lymphoma46–49. We found moderate membranous and/or cytoplasmic 
staining of human pancreatic cancer tissue microarrays and cell pellets with anti-CD26 mAb KU44.13A (Fig. 7). 
Although there is no published research on the immunohistochemical staining of CD26 in pancreatic cancer, it 
has been shown that stromal CD26 expression following preoperative chemoradiotherapy has significant asso-
ciation with tumour recurrence and poor prognosis in patients with rectal cancer50. A positive association was 
also reported between high CD26 expression and tumour stage, development of metastasis and poor outcome in 
patients with colorectal cancer51. Finally, the results of a recent phase 1 clinical trial of the humanised anti-CD26 
mAb YS110 in patients with mesothelioma, renal cell carcinoma and urothelial carcinoma CD26-expressing 
tumours showed a favourable safety profile and encouraged disease stabilisation in a subset of patients52. Further 
studies with our novel mAb KU44.13A in a larger panel of patients’ tumour specimens are warranted and should 
unravel the relative expression, prognostic significance and predictive value of CD26 in patients with pancreatic 
cancer as well as other cancer types.
In conclusion, in this study, we reported the production of two novel monoclonal antibodies against inte-
grin α3 and CD26 on human pancreatic cancer cells, using the liver metastasis pancreatic cancer cell line 
CFPAC-1 as immunogen. These antibodies would be excellent tools for investigating the diagnostic, prognos-
tic and predictive value of such antigens in pancreatic cancer, and studying their roles in the complex biology 
of pancreatic cancer and other cancer types. Further investigation are warranted to determine the therapeu-
tic potential of these mAbs, particularly the conjugated and/or humanised versions with more effector ADCC 
(antibody-dependent cell-mediated cytotoxicity) and/or CDC (complement-dependent cytotoxicity) functions, 
for use in antibody-based targeted therapy of tumours with overexpression of these antigens53,54.
Methods
Cancer cell lines and cell culture. A panel of ten human pancreatic cancer cell lines (BxPC-3 
[RRID:CVCL_0186], Capan-2 [RRID:CVCL_0026], MIA PaCa-2 [RRID:CVCL_0428], PANC-1 
[RRID:CVCL_0480],  AsPC-1 [RRID:CVCL_0152],  HPAF-II [RRID:CVCL_0313],  CFPAC-1 
[RRID:CVCL_1119], Capan-1, Hs766T [RRID:CVCL_0334] and FA-6) were used in this study and cultured as 
described previously9,55. SP2 myeloma cells (RRID:CVCL_2199) were purchased from European Collection of 
Cell Cultures (ECACC, UK). HN5 (head and neck cancer cells), SKOV-3 and CaOV-3 (ovarian cancer cells), DiFi 
(colorectal cancer cells), A172 (glioblastoma cells) and SP2 myeloma cells were grown in Dulbecco’s Modified 
Eagle’s Medium supplemented with 10% FBS and antibiotics. All culture media and additives were purchased 
from Sigma Aldrich, UK. MIA PaCa-2, PANC-1, and Capan-1 were authenticated by American Type Culture 
Collection (ATCC, UK).
Generation and screening of novel monoclonal antibodies. The mice immunisation was per-
formed at St George’s University of London, following ethical approval and under Home Office animal license as 
described previously9. All experiments were performed in accordance with relevant guidelines and regulations. 
A group of female BALB/c mice (aged 5–6 weeks) were immunised subcutaneously (s.c) at two sites and intra-
peritoneally (i.p.) with a total number of 10 million CFPAC-1 human pancreatic cancer cells per immunisation 
per mouse (3 sites; 100 μl per site). Immunisation was repeated 2 times every 2 weeks and the final injection was 
administered 3–4 days before collection of lymphocytes from the spleen of immunised mice. B-lymphocytes 
derived from the spleen of immunised mice were fused with SP2 myeloma cells by 50% polyethylene glycol 
(PEG; Sigma Aldrich). Cells were cultured in HAT medium (Sigma Aldrich) supplemented with 20% FBS, 10% 
Hybridoma Cloning Supplement (Santa Cruz Biotechnology, USA) and antibiotics.
Antibodies secreted from novel hybridomas were screened by ELISA as described previously9. Newly formed 
positive hybridomas were selected, cloned twice by limiting dilution technique, adapted to growth medium con-
taining 3% FBS, grown in roller bottles and the hybridoma supernatants were harvested and purified for further 
studies as described below.
Flow cytometry. The cell surface expression of target antigens recognised by novel mAbs was determined 
using flow cytometry as described previously9,56. Briefly, cells were trypsinised and approximately 1 × 106 tumour 
cells were incubated by rotation for 1 h at 4 °C with novel mouse mAbs KU44.22B or KU44.13A (10 μg/ml) or 
control (i.e. PBS), followed by incubation with FITC-conjugated goat anti-mouse IgG secondary antibody (1:200; 
STAR9B, AbD Serotec; RRID:AB_321920) for 45 min at 4 °C. A minimum of 10,000 events were recorded by 
excitation with an argon laser at 488 nm and analysed using the FL-1 detector (FITC detector; 525 nm) of a BD 
FACScalibur flow cytometer using CellQuest Pro software (Becton-Dickinson Ltd, UK; RRID:SCR_014489).
Isotyping and purification of novel monoclonal antibodies. Isotyping of novel mAbs was determined 
using a mouse mAb isotyping kit (AbD Serotec, UK) according to the manufacturer’s protocol and the antibodies 
were purified by affinity chromatography as described previously9. Briefly, novel mouse mAbs were purified by 
salt fractionation (solid ammonium sulphate ([NH4]2SO4; 45% of saturation − 270 g/L; Fisher Scientific) followed 
by affinity chromatography using a 5 ml HiTrap Protein G HP column in an ÄKTAprime plus chromatography 
system (GE Healthcare, UK), as described previously9. The purified antibodies were filtered through a 0.2 µm 
syringe filter (Merck Millipore, UK), aliquoted and stored at −20 °C for further studies.
1 0Scientific RepoRtS |          (2020) 10:537  | https://doi.org/10.1038/s41598-019-57287-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Internalisation studies. Immunofluorescence staining of tumour cells and ELISA were used to determine 
whether treatment with novel antibodies resulted in down-regulation of the target antigen as described previ-
ously9. Briefly, pancreatic cancer cells were grown to near confluency in RPMI/10% FBS in Lab-Tek 8-well cham-
ber slides (VWR, UK) or 96-well plates, respectively. Cells were incubated with mAbs KU44.22B or KU44.13A 
(50 µg/ml) or control (i.e. PBS/1%BSA alone) for 1 h at 4 °C to allow antibody binding, followed by incubation at 
37 °C for 30 min to allow antibody internalisation. A control slide was maintained at 4 °C. Cells were fixed with 4% 
formaldehyde for 10 min, the cell membrane permeabilised with 0.5% Triton-X 100 for 15 min and non-specific 
binding blocked with PBS/1%BSA for 1 h at 4 °C. Cells in immunofluorescence slides were then incubated 
with Alexa Fluor 488 secondary antibody (1:200; Fisher Scientific; RRID:AI_1001) for 1 h at 4 °C, mounted in 
Vectashield with DAPI (Vector laboratories, UK) and examined using Nikon eclipse i80 microscope and Nikon 
NIS-Elements software as described previously (RRID:SCR_014329)57. Cells in ELISA plates were incubated 
under the same conditions above with the primary antibodies and then incubated with HRP-conjugated rabbit 
anti-mouse (1:1000, STAR13B, AbD Serotec; RRID:AB_321921). Following several washes, the absorbance of 
each sample was measured at 450 nm as described previously9
Effect of novel mAbs on growth and migration of pancreatic cancer cells. The effect of novel 
mAbs on the growth of human cancer cell lines was investigated using the Sulforhodamine B (SRB) colorimet-
ric assay9,58. Gen5 software was used to determine the IC50 through non-linear least squares curve fitting, as 
described previously56,59.
The effect of novel mAbs on the migration of human pancreatic cancer cells BxPC-3, AsPC-1 and CFPAC-1 
was investigated using the IncuCyte ZOOM® Live-Cell Imaging instrument (Essen Bioscience, UK) as described 
previously9. Approximately 1 × 103 cancer cells per well were seeded in duplicate in an IncuCyte™ ClearView 
96-well Cell Migration Plate (Essen Bioscience, UK) along with 300 nM mAbs or control (i.e. medium alone). 
Cells were allowed to settle for 15 min at room temperature before transfer to an incubator at 37 °C for 30 min 
to pre-incubate the cells in the presence of treatment. Then, 200 μl of chemoattractant (i.e. 10% FBS medium) 
or control (i.e. 0.5% FBS medium) were added to the appropriate wells of the reservoir plate and the insert plate 
placed into the pre-filled reservoir plate. The plate was then transferred to the IncuCyte ZOOM® Live-Cell 
Imaging Instrument (Essen Bioscience) and allowed to warm to 37 °C for 15 min before any condensation accu-
mulated on the plate lid or bottom was wiped away. The plate was imaged at 10x objective using the Chemotaxis 
Scan Type - Phase channel. The IncuCyte™ Chemotaxis Cell Migration Software Module (Essen Bioscience) was 
used for data analysis. Whole-well images of cells on both the bottom and the top of the plate membrane were 
captured every 2 h over 48 h and all images were processed using automatic algorithms to quantify cell area on 
each side of the membrane.
Immunoprecipitation and mass spectrometry. To identify the target antigens recognised by the novel 
antibodies, immunoprecipitation and mass spectrometry were performed using protein identification service 
provided by the University of York (UK) as described previously9. Briefly, novel mAbs (5 μg) were incubated 
overnight at 4 °C by gentle rotation (14 rpm) with 1 ml AsPC-1 (mAb KU44.13A) or CaOV-3 (mAb KU44.22B) 
tumour cell lysates (prepared with lysis buffer containing 50 mM Tris-HCl pH 7.2, 150 mM NaCl, 2 mM MgCl2, 
2 mM CaCl2, 0.1% NaN3, 100 mM DTT, 1% Triton X-100 and 50 mM N-ethylmaleimide), and then incubated 
with 50 μl pre-washed Dynabeads sheep anti-mouse IgG for 1 h at 4 °C (ThermoFisher Scientific). The immu-
nocomplexes were captured on a DynaMag™-2 for 2 min, the supernatants aspirated, and the samples washed 
3 times with PBS. The complexes were then eluted by mixing beads with LDS sample buffer (25% NuPAGE LDS 
buffer [4 × ], 10% reducing agent [10 × ] and 65% distilled water; Invitrogen, UK), heated to 95 °C for 5 min and 
analysed by SDS-PAGE. The SDS-PAGE gels were stained with SimplyBlue™ SafeStain (ThermoFisher Scientific) 
and the protein bands were excised (Supplementary Fig. 3A,B), and in gel digested with trypsin for subsequent 
mass spectrometry analysis.
Identification of isolated protein was performed by mass spectrometry under contract at the University of 
York’s protein identification facility, as described previously9. The UniProt_human_SP database was used for 
protein identification.
Western blotting. The ability of the novel antibodies to recognise the target antigen in Western blot 
was investigated as described previously9. Briefly, proteins immunoprecipitated with novel mAbs KU44.22B 
and KU44.13A (5 µg) or commercial mAbs anti-integrin α3 (2 µg; sc-374242; Santa Cruz Biotechnology, 
UK; RRID:AB_10985868) or anti-CD26 (2 µg; ab89398; Abcam, UK; RRID: AB_2277416) were analysed 
by SDS-PAGE under reducing conditions, prior to Western blotting. The transfer of proteins from 4–12% 
Bis-Tris-gels to Immobilon-FL PVDF membranes (Merck Millipore, UK) was performed using the XCell IITM 
Mini-Cell Blot Module kit (Invitrogen, UK) at a constant voltage of 30 V on ice for 2 h. PVDF membranes were 
probed with novel mAbs (30 μg/ml), commercial anti-integrin α3 mouse mAb (1:100 dilution) or commercial 
anti-CD26 rat mAb (1:500 dilution) overnight at 4 °C and subsequently incubated for 1 h at room temperature 
with secondary goat anti-mouse antibody (1:10,000; RRID:926_32210) or secondary goat anti-rat antibody 
(1:5,000; RRID:925-68076, both from LI-COR Biosciences, UK) respectively. For visualisation, the blots were 
analysed using the Oddysey® CLx instrument (LI-COR Biosciences; RRID:SCR_014579).
Immunohistochemical staining. AsPC-1 and Capan-2 cancer cell pellets and human pancreatic cancer 
tissue microarrays (PA483e, Insight Biotechnology/US Biomax) were used to determine whether novel monoclo-
nal antibodies immunodetect the target antigens in formalin-fixed paraffin-embedded tissue sections using the 
VENTANA BenchMark ULTRA IHC/ISH System (Roche, UK). Tissue sections were deparaffinised and rehy-
drated through a series of alcohols followed by heat induced antigen retrieval with standard CC1 (Tris-EDTA 
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buffer pH 7.8) at 95 °C for 36 min and incubation for 1 h with either mAb KU44.22B (15 µg/ml) or mAb KU44.13A 
(10 µg/ml). An anti-mouse IgG detection system (UltraView Universal DAB Detection Kit, Ventana) was used 
for amplification and primary antibody detection. The slides were then counterstained with haematoxylin II for 
8 min followed by Bluing reagent. The slides were then washed, dehydrated, cleared, mounted in DPX mounting 
medium (VWR) and coverslipped as described previously60.
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information Files).
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